ARQT
ARCUTIS BIOTHERAPEUTICS INC
$10.24
Earnings Summary
Revenue | $0Mn |
Net Profits | $-34.05Mn |
Net Profit Margins | -Inf% |
Highlights
ARCUTIS BIOTHERAPEUTICS INC’s revenue jumped NaN% since last year same period to $0Mn in the Q4 2020. On a quarterly growth basis, ARCUTIS BIOTHERAPEUTICS INC has generated NaN% jump in its revenue since last 3-months.
ARCUTIS BIOTHERAPEUTICS INC’s net profit fell -170.92% since last year same period to $-34.05Mn in the Q4 2020. On a quarterly growth basis, ARCUTIS BIOTHERAPEUTICS INC has generated 10.88% jump in its net profits since last 3-months.
ARCUTIS BIOTHERAPEUTICS INC’s net profit margin jumped NaN% since last year same period to -Inf% in the Q4 2020. On a quarterly growth basis, ARCUTIS BIOTHERAPEUTICS INC has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the ARCUTIS BIOTHERAPEUTICS INC post its latest quarter earnings
EPS Estimate Current Quarter | -1.38 |
EPS Estimate Current Year | -1.38 |
Highlights
ARCUTIS BIOTHERAPEUTICS INC’s earning per share (EPS) estimates for the current quarter stand at -1.38 - a 17.37% jump from last quarter’s estimates.
ARCUTIS BIOTHERAPEUTICS INC’s earning per share (EPS) estimates for the current year stand at -1.38.
Key Ratios
Key ratios of the ARCUTIS BIOTHERAPEUTICS INC post its Q4 2022 earnings
Return on Assets (ROA) | -0.44 |
Return on Equity (ROE) | -1.23 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ARCUTIS BIOTHERAPEUTICS INC’s return on assets (ROA) stands at -0.44.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ARCUTIS BIOTHERAPEUTICS INC’s return on equity (ROE) stands at -1.23.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2019-06-30 | 0 | -0.43 | -Inf% |
2019-09-30 | 0 | -7.6 | -Inf% |
2020-03-19 | -9.21 | -6.18 | 32.9% |
Company Information
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis' robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company's lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.
Organisation | ARCUTIS BIOTHERAPEUTICS INC |
Headquarters | 3027 Townsgate Road, Westlake Village, CA, United States, 91361 |
Employees | 268 |
Industry | Health Technology |
